US Mouth Ulcer Therapeutics Market Analysis

US Mouth Ulcer Therapeutics Market Executive Summary

The US Mouth Ulcer Therapeutics Market is at around $638.4 Mn in 2023 and is projected to reach $728.3 Mn in 2030, exhibiting a CAGR of 1.9% during the forecast period 2023-2030.

Mouth ulcers, also known as canker sores, are classified into three main types: minor aphthous ulcers which are the most common small oval lesions, major aphthous ulcers that are larger and deeper causing more pain, and herpetiform ulcers which start as multiple small ulcers that can merge into one large ulcer. While the exact cause is unknown, several risk factors have been identified including stress, anxiety, hormonal changes, nutritional deficiencies (iron, vitamin B12, folic acid, zinc), certain medical conditions like celiac disease, Crohn's disease, and HIV/AIDS, as well as trauma from dental work, braces, or ill-fitting dentures. In most cases, mouth ulcers are self-limiting and resolve within 1-2 weeks without treatment. However, complications can arise such as secondary infection, severe pain affecting one's ability to eat or drink properly, and potential scarring in cases of severe recurrent ulcers. Prevention involves reducing stress, avoiding potential food triggers like citrus fruits, nuts, and chips, using soft-bristled toothbrushes and waxed dental floss, and replacing toothpaste if it seems to be a trigger. Treatment involves symptomatic relief with topical gels containing anaesthetics, antiseptics, and antibiotics, as well as supportive care with multivitamins or vitamin supplements, antipyretics, and antibiotics. Medications include antibiotics, oral painkillers, oral steroids, antiseptics, chlorhexidine gluconate mouthwash, and sucralfate. Home care includes good oral hygiene, avoiding trigger foods, warm saline gargles, ice packs, and a balanced diet. Medical attention is necessary if the ulcers fail to heal within a week or two, are unusual, spreading, or large, or if there is severe pain, fever, or difficulty while chewing, talking, or swallowing.

Prevalence rate aphthous ulcers are the most common oral mucosal disease in US. They affect 20% of the population, with the incidence rising to more than 50% in certain groups of students in professional schools. The market therefore is driven by significant factors like rising awareness about oral hygiene, growing focus on preventive care and increasing incidence of oral diseases, however, factors such as limited accessibility, availability of substitute treatments, and presence of home remedies limit market growth.

The industry is primarily dominated by players such as AstraZeneca, Teva Pharmaceuticals, Takeda Pharmaceuticals, AbbVie, Bayer Inc, Bristol-Myers Squibb Company, GlaxoSmithKline PLC, Pfizer, Inc, Merck among others.

Market Dynamics

Market Growth Drivers

Rising Awareness of Oral Hygiene: Public awareness campaigns and educational initiatives are promoting the importance of oral hygiene, leading to a greater understanding of the causes and prevention methods for mouth ulcers. This increased awareness is driving demand for effective treatments and products that can help manage and prevent mouth ulcers.

Growing Focus on Preventive Care: The emphasis on preventive care in healthcare is encouraging individuals to take proactive steps to maintain good oral health, which includes regular check-ups, proper brushing and flossing, and avoiding habits that can contribute to mouth ulcers. This shift towards preventive care is driving the demand for mouth ulcer treatments.

Increasing Prevalence of Mouth Ulcers: The high prevalence of tobacco consumption in the United States is a significant contributor to the rise in mouth ulcers. In 2021, an estimated 11.5% (28.3 Mn) of U.S. adults currently smoked cigarettes. Tobacco use can cause mouth ulcers, and the increasing awareness of the risks associated with tobacco use is driving the demand for treatments.

Market Restraints

Limited Accessibility to Pharmaceuticals: The high cost of pharmaceutical treatments for mouth ulcers can limit accessibility, particularly in developing and underdeveloped countries. This can lead to a lower demand for these treatments and Limited insurance coverage for mouth ulcer treatments can also restrict accessibility, making it difficult for individuals to afford the treatments they need.

Substitute Traditional Treatments: The availability of herbal remedies and traditional treatments for mouth ulcers can limit the demand for pharmaceutical treatments. Some individuals may prefer these alternative treatments due to their perceived safety and effectiveness.

Cost-Effective Treatment Procedures: The availability of cost-effective alternatives, such as over-the-counter treatments or home remedies, can limit the demand for pharmaceutical treatments. Individuals may opt for these alternatives due to their lower cost and perceived effectiveness.

Regulatory Landscape and Reimbursement Scenario

The Centres for Disease Control and Prevention (CDC) serves as the primary regulatory body in the United States that oversees pharmaceutical products and diagnostic tools related to mouth ulcers, while also playing a vital role in raising awareness about the disease among the general public. Although the Food and Drug Administration (FDA) is responsible for approving drugs and diagnostic tests, the CDC provides guidance and recommendations on their appropriate use for mouth ulcers prevention and treatment.

The CDC closely monitors the incidence and prevalence of mouth ulcer cases in the U.S. through its surveillance systems, and this data guides public health policies, resource allocation, and awareness efforts. Additionally, the CDC develops and promotes evidence-based strategies for preventing the occurrence of mouth ulcers. The agency offers educational resources, clinical guidelines, and training for healthcare providers on screening, diagnosis, management, and treatment.

Furthermore, the CDC plays a crucial role in raising public awareness about through educational campaigns, community outreach programs, and dissemination of informational materials, aiming to increase knowledge about transmission, symptoms, testing, and available resources. Importantly, the CDC collaborates with state and local health departments, community organizations, and other stakeholders to coordinate mouth ulcers prevention, control, and awareness efforts across the nation.

Competitive Landscape

Key Players

Here are some of the major key players in the US Mouth Ulcers Therapeutics Market:

• AstraZeneca
• AbbVie
• Pfizer, Inc
• Merck
• Teva Pharmaceutical
• Bristol-Myers Squibb Company
• Bayer
• GlaxoSmithKline plc.
• Takeda Pharmaceuticals
• Sanofi